Evorpacept

Phase 3Protein / enzyme

AALX Oncology Inc.

Evorpacept is one of 136 small molecule programs targeting Breast Cancer Metastatic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

135

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast Cancer MetastaticRecruiting

Oropharynx CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

AgeRecruiting

Breast Cancer MetastaticPhase 2

Recruiting

Oropharynx CancerPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

AgePhase 2

Recruiting

Competition

Competitive Landscape

193 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

44 2

Opdivo

Bristol-Myers Squibb

Phase 3

24 3

Camptosar

Pfizer

Phase 3

23 4

Keytruda

Merck & Co.

Phase 3

19 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

55 6

Taxotere

AAvyxa

Phase 3

45 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

91 8

Avastin

Roche

Phase 3

11 9

Abraxane

Cyramza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Age

NCT04643002

Q4 2028

Phase 2Recruiting

Breast Cancer Metastatic

NCT07007559

Q4 2029

Phase 2Active, not recruiting

Oropharynx Cancer

NCT05787639

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Active, not recruiting·AALX Oncology Inc.·Phase 2·NCT04675294·189 enrolled

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Active, not recruiting·AALX Oncology Inc.·Phase 2·NCT04675333·172 enrolled

Myelodysplastic Syndrome1 trial

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Terminated·AALX Oncology Inc.·Phase 1·NCT04417517·65 enrolled

Gastric Cancer1 trial

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Active, not recruiting·AALX Oncology Inc.·Phase 2/3·NCT05002127·127 enrolled

Lymphoma1 trial

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Completed·AALX Oncology Inc.·Phase 1·NCT03013218·174 enrolled

Acute Myeloid Leukemia1 trial

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Terminated·AALX Oncology Inc.·Phase 1·NCT04755244·14 enrolled

6 more indications

Age1 trial

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT04643002·258 enrolled

Urothelial Carcinoma1 trial

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Completed·AALX Oncology Inc.·Phase 1·NCT05524545·36 enrolled

Microsatellite Stable Metastatic Colorectal Cancer1 trial

A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer

Terminated·UUniversity of Colorado, Denver·Phase 2·NCT05167409·19 enrolled

Breast Cancer Metastatic1 trial

Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Recruiting·AALX Oncology Inc.·Phase 2·NCT07007559·120 enrolled

Oropharynx Cancer1 trial

Neoadjuvant Radiation and Evorpacept (ALX148) in Combination With Pembrolizumab In Patients With Previously Untreated Locally Advanced, Resectable, HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT05787639·28 enrolled

Cancers1 trial

A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Preclinical·NCT05027139·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Evorpacept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Evorpacept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Evorpacept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ALX Oncology Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: AALX Oncology Inc.

Evorpacept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Myelodysplastic Syndrome1 trial

Gastric Cancer1 trial

Lymphoma1 trial

Acute Myeloid Leukemia1 trial

Age1 trial

Urothelial Carcinoma1 trial

Microsatellite Stable Metastatic Colorectal Cancer1 trial

Breast Cancer Metastatic1 trial

Oropharynx Cancer1 trial

Cancers1 trial

References

Drug Info

Quick Facts

Related News